Physiological mechanisms underlying the use of *Garcinia Kola* Heckel in the treatment of asthma

M I Ebomoyi and A K Okojie

Introduction

Historically, plants have provided a source of inspiration for novel drug compounds, as plant-derived medicines have made large contributions to human health and well-being. Their role is two-fold in the development of new drugs: (1) they may become the basis for the development of new medicine, i.e. a natural blueprint for the development of new drugs; or (2) a phytomedicine to be used for the treatment of disease. Though there is availability of various orthodox drugs for the treatment of respiratory tract diseases in Nigeria, there is increasing interest in herbal remedies.[1] The seeds of *Garcinia kola* (GK) form a major part of the herbal preparation used in traditional African medicine practice for the treatment of various respiratory tract diseases, including asthma.[2]

Garcinia kola Heckel belongs to the family Guttiferae, and it is commonly called bitter kola. In Nigeria, the plant is valued because of its edible nuts. The plant exhibits very potent pharmacological activities such as anti-oxidant, anti-bacterial, anti-viral, anti-fungal and anti-inflammatory properties.[3–7] The anti-oxidant property of GK is attributed to its very high content of ascorbic acid.[8] Phytochemistry of GK has shown its contents to include benzophenones, xanthones, biflavonoids, alkaloids, phenols, tannins, and saponins.[8–15]

Asthma is characterised by episodic or chronic wheezing, cough, and feeling of tightness in the chest as a result of bronchoconstriction.[16] The fundamental cause is still unknown despite intensive research. However, three abnormalities are present: airway obstruction that is at least partially reversible, airway inflammation, and airway hyper-responsiveness to a variety of stimuli. A link to allergy has long been recognised, and plasma immunoglobulin E (IgE) levels are often elevated.[17]

Because of the importance of GK as a herb commonly used in herbal medicine for the treatment of asthma, it becomes necessary to determine the physiological mechanism(s) underlying its use. This paper reviews the function(s) of its phytochemical contents and how they are beneficial in the treatment of asthma.

M I Ebomoyi and A K Okojie
Department of Physiology, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Benin City, Nigeria.
Correspondence to: Maureen Ebomoyi. Email: maureenebomoyi@gmail.com

Garcinia kola

Garcinia kola Heckel 'bitter kola' is popular in southern Nigeria. The plant is extensively used in herbal medicine and as food. It is usually found in the tropical rain forest region of West Africa. It prevails as a multi-purpose tree crop in the home gardens of southern Nigeria.[18] The tree is usually cultivated within villages in southern Nigeria. It grows to a height of about 12–14 m and produces reddish, yellowish, or orange-coloured fruit.[8,19] Each fruit contains two to four yellow seeds and a sour tasting pulp. The seeds when chewed have a bitter, astringent taste. The flowering of the plant occurs between December and January while the fruits mature between June and August.

Garcinia kola is highly valued for medicinal use.[20,21] The seeds are chewed as an aphrodisiac or used to cure cough, dysentery, or chest colds in herbal medicine.[22] This plant has been referred to as a 'wonder plant' because every part of it has been found to be of medicinal importance.[23] GK could serve as a raw material for pharmaceutical industries.[24] GK is used in folklore remedies for the treatment of ailments such as liver disorders, hepatitis, diarrhoea, laryngitis, bronchitis, and gonorrhoea.[7,25] The seed is used to prevent and relieve colic; it can also be used to treat headache.[26] The plant can be used in the treatment of stomach ache and gastritis.[27] Iwu[7] reported the use of this plant for the treatment of jaundice, high fever, and as purgative. Administration of GK seed extract caused an increase in testosterone production in Sprague–Dawley rats which is thought to be due to its anti-oxidant properties.[28,29] Also, Adesanya et al[19] confirmed the spermatogenic and tissue enhancing effect of GK extract in male Wistar rats. David et al[30] showed that GK extract exhibits a dilatory effect on the alveolar ducts, alveolar sacs, and alveoli thereby improving respiratory activities; in Swiss albino mice this may be due to its anti-oxidant properties. GK has been shown to inhibit smooth muscle activity. It relaxes the smooth muscles of the uterus and the intestine.[31] Although GK lacks caffeine,[32] its alkaloid and biflavonoids fractions are said to relax the smooth muscles.[31] GK has a bronchodilatory effect.[33,34]

Asthma

Asthma is a very common chronic disease involving the respiratory system. There are three basic abnormalities in asthma:

1. airway obstruction that is at least partially reversible;
2. airway inflammation;
3. airway hyper-responsiveness to a variety of stimuli. Public attention in the developed world has recently focused on asthma because of its rapidly increasing prevalence, affecting up to one in four urban children.[35] Asthma is caused by a complex interaction of environmental and genetic factors that researchers do not yet fully understand.[36]

Environmental tobacco smoke, especially maternal cigarette smoking, is associated with high risk of asthma prevalence and asthma morbidity, wheeze, and respiratory infections.[37] Poor air quality from traffic pollution or high ozone levels has been repeatedly associated with increased asthma morbidity and has a suggested association with asthma development.[37] This however needs further research. Caesarean sections have been associated with asthma when compared with vaginal birth; a meta analysis found a 20% increase in asthma prevalence in children delivered by caesarean section compared with those who were not. It was observed that this was due to modified bacterial exposure during caesarean section compared with vaginal birth, which modifies the immune system.[38] There is growing evidence that stress may influence asthma and other disease by influencing the immune system.[37] Antibiotic use early in life has been linked to development of asthma in several studies; it is thought that antibiotics make one susceptible to development of asthma because they modify gut flora, and thus the immune system.[39]

Over 100 genes have been associated with asthma in at least one genetic association study.[40] However, such studies must be repeated to ensure that the findings are not due to chance. Many of these genes are related to the immune system or to modulating inflammation. Moreover, even among this list of highly replicated genes associated with asthma, the results have not been consistent among all of the populations that have been tested.[40] This indicates that these genes are not associated with asthma under every condition, and that researchers need to do further investigation to establish the complex interactions that cause asthma. Research suggests that some genetic variants may only cause asthma when they are combined with specific environmental exposures and otherwise may not be risk factors for asthma.[36]

The fundamental problem in asthma appears to be immunological. In the immunologic model, asthma is a disease mediated by reaginic (IgE) antibodies bound to mast cells in the airway mucosa. On re-exposure to an antigen, antigen–antibody interaction on the surface of mast cells triggers both the release of mediators stored in the cells granules and the synthesis and release of other mediators.[16] The agents responsible for the early reaction mediating bronchoconstriction – including histamine, tryptase and other neural proteases, leukotrienes C4 and D4, and prostaglandin – cause muscle contraction and vascular leakage.[16] Cytokines produced by T-helper type 2 (TH_2) lymphocytes, especially grannlocyte macrophagen–

colony stimulating factor (GM–CSF) and interleukins (IL)-4, -5, -9, and -13, which attract the active eosinophils and stimulate IgE production by B lymphocytes, are thought to be responsible for more sustained bronchoconstriction, cellular infiltration of the airway mucosa, and mucus hypersecretion of the late asthmatic reaction.[41] These chronic inflammatory disorders of the airways that lead to tissue injury and subsequent structural changes are collectively called airway remodelling.[42] TH_1 T-cells make interferone-γ, lymphotoxin, and IL-2. TH_1 and TH_2 cells differentiate into polarised populations from a common precursor. After development, they are believed to inhibit development of other cell types. TH_1 cells play a dominant role in controlling intracellular pathogens like tuberculosis, while TH_2 cells play a dominant role in controlling extracellular pathogens like parasites and mites, and allergens like dusts and pollens.[43] The absence of either of these populations leads to enhanced immunopathology, even in conditions classically thought to depend on the other cell types.

Airway remodelling includes:
1. an increase in overall wall thickness;
2. an increase in airway fibrosis;
3. an increase in smooth muscle mass;
4. abnormality in composition of the extracellular matrix;
5. an increase in vascularity.[42]

These changes have attracted interest due to the increased realisation that they may account for aspects of asthmatic physiology that are poorly addressed with current anti–inflammatory strategies.[44] A few studies have addressed the issue of response of putative remodeling mediators to therapy. Insulin-like growth factor (IGF)–β appears to be resistant to steroid therapy, whether or not there is a reduction in measures of airway remodelling.[45,46] Despite the suggestion that airway remodelling explains the lack of response to therapy of some patients, no study has specifically shown that those patients who either fail to respond to therapy or progress despite therapy do in fact show airway remodelling that fails to respond or progresses despite a reduction in inflammation.[47] This observation could be due to disease heterogeneity. If this hypothesis was true, it would ultimately be necessary to characterise the pathological basis of each patient's physiology before determining which therapy would be most beneficial in reversing or preventing airway remodeling in that individual patient.[47]

The mechanisms underlying bronchial reactivity, such as ozone exposure, allergen inhalation, and infection with respiratory viruses, also cause airway inflammation. In humans, the increase in bronchial reactivity induced by ozone is associated with an increase in the number of polymorphonuclear leukocytes found in fluid obtained by bronchial lavage or from bronchial mucosa biopsies. The increase in reactivity due to allergen inhalation is associated with an increase in both eosinophils and polymorphonuclear leukocytes in bronchial lavage fluid. Whatever the mechanisms responsible for bronchial hyper-reactivity, bronchoconstriction itself seems to

result not simply from the direct effect of the released mediators but also from their activation of neural or humoral pathways.

Actions of xanthones

Xanthones have anti-asthmatic activity by dependently inhibiting the Ca^{2+} influx induced by either norepinephrine or high K^+, suggesting that xanthone might act as a blocker of both receptor–operated and voltage–dependent Ca^{2+} channels.[6] Furthermore, xanthone causes increase in the level of intracellular cyclic adenosine 3′, 5′–monophosphate (cAMP) but not cyclic guanosine 3′, 5′–monophosphate (cGMP) content.[6] Chairungsrilerd et al[21] reported that xanthone showed inhibitory effects on cAMP phosphodiesterase. Intracellular levels of cAMP can be increased by β-adrenoceptor agonists, which increase the rate of its synthesis by adenyl cyclase (AC) or by phosphodiesterase (PDE) inhibitors such as xanthone, which slow the rate of its degradation.

Actions of flavonoids

Flavonoids have anti–asthmatic activity by inhibiting platelet-activating factor (PAF), phospholipase A_2 (PLA_2) and phosphodiesterase (PDE).[48,49] Flavonoids protect against allergies, inflammation, free radicals, and platelet aggregation.[50-53] These observations support the importance of GK in traditional medicine for the treatment of various conditions.

Flavonoids have been shown to exhibit a predilection to inhibit histamine release stimulated by IgE-dependent ligands.[54] Copper, a transitional metal, most effectively blocks the inhibitory activity of flavonoids, possibly through a chelation mechanism.[55] Zinc deficiencies can lead to excess copper levels, since zinc and copper compete for absorption. Also, a high intake of vitamin C and zinc decrease the absorption of copper. Intake of GK will therefore reduce the inhibition of anti-histamine activity of flavonoids by copper because of its high content of vitamin C and zinc. Middleton and Drzewiecki[56] noted that naturally occurring plant flavonoids affect a variety of cell activation phenomena including the secretion of histamine from human basophils. They also showed that flavonoids inhibit the degranulation of mast cells. Degranulation of mast cells would release not only histamine, but all the mediators of the allergy response.

Simoes,[57] reported that flavonoids exhibited anti-spasmodic and anti–inflammatory properties induced by acetylcholine, histamine, noradrenaline, and barium chloride in four different smooth muscles. In addition, flavonoids inhibit antigen-induced release of histamine from mast cells, basophils and also inhibit contractions induced by histamine, acetylcholine and prostaglandin E_2 (PGE_2). It was noted that this effect was concentration dependent.

Flavonoids inhibit phospholipid metabolism and 5- lipoxygenase (5–LO). Leukotrienes are derived from arachidonic acid through 5–LO and the nucleophilic attack to produce peptidoleukotrienes. These 5–LO products mediate constriction of airway smooth muscles, leukocyte chemotaxis,[58,59] and vascular permeability.[58,60] Therefore, inhibiting 5–LO can attenuate leukotriene production.

The presence of phenol in GK further indicated that it could act as anti-inflammatory, anti-oxidant and immune enhancer.[61] Phenols have been shown to block specific enzymes that cause inflammation. They also modify the prostaglandin pathways and thereby protect platelets from clumping.[8]

Conclusion

From this review, the following could be responsible for the beneficial effects of underlying physiological mechanisms of *Garcinia kola* in the treatment of asthma:

- Inhibition of Ca^{2+} influx by acting as a blocker of both receptor-operated and voltage-dependent Ca^{2+} channels.
- Increasing the intracellular levels of cAMP by inhibiting the effects of phosphodiesterase.
- Inhibition of histamine release stimulated by IgE-dependent ligands.
- Inhibition of platelet-activating factor and platelet aggregation.
- Reducing the inhibition of the anti-histamine activity of flavonoids by copper.
- Inhibition of 5-lipoxygenase (5-LO) pathway, thereby attenuating leukotriene production.

In conclusion, *Garcinia kola* appears to be very promising in the treatment and management of asthma. There is therefore the need to further examine the effects of its various phytochemical contents on respiratory smooth muscle, with a view to possibly formulating its extracts or active constituents as medicines.

References
1. Ebomoyi MI, Iyawe VI. Peak expiratory flow rate (PEFR) in young adult Nigerians following ingestion of *Garcinia kola* (Heckel) seeds. *Afr J Biomed Res* 2000; 3: 187–9.
2. Ebomoyi MI, Iyawe VI, Egbagbe EE. Effect of *Garcinia conrauana* ingestion on airway resistance in a population of healthy adult Nigerians. *Nig J Heal Biom Sci* 2004; 3: 24–7.
3. Adegboye MF, Akinpelu DA, Okoh AI. The bioactive and phytochemical properties of *Garcinia kola (Heckel)* seed extracts on some pathogens. *Afr J Biotech* 2008; 7: 3934–8.
4. Mackeen MM, Ali AM, Lajis NH, et al. Antifungal Garcinia acid esters from the fruits of *Garcinia atroviridis*. *Z Naturforch* 2002; 57: 291–5.
5. Iwu MM, Duncan AR, Okunyi CO. New antimicrobials of plant origin. In *Perspectives on New Cops and New Uses*. Ed J Janick, 1999. Alexandria, VAASHS Press: pp 457–62.
6. Chen YW, Kang JJ. Mechanism of vasorelaxation of thoracic aorta caused by xanthone. *Eur J Pharmacol* 1997; 336: 23–8.
7. Iwu MM. *Handbook of African Medicinal Plants*. 1993. Boca Raton: CRC Press Inc. pp 223–4.
8. Okwu DE. Phytochemical, Vitamins and Mineral contents of two Nigerian medicinal plants. *Int J Mol Med Adv Sci* 2005; 1: 375–81.
9. Farombi EO, Akanni OO, Emerole GO. Antioxidant and scavenging activities of flavonoid extract (kolaviron) of *Garcinia Kola* seeds in vitro. *Pharm Biol* 2002; 40: 107–16.
10. Okunyi CO, Tantalia AW, Hicks RP, et al. Capillary electrophoresis determination of biflavonones from *Garcinia kola* in three traditional African medicinal formulations. *Plant Med* 2002; 68: 440–4.

11. Tarashima K, Kondo Y, Aqil M, Waziri M. A study of bioflavonones from stem of *Garcinia Kola (Guttiferae). Heterocytes* 1999; 50: 238–90.

12. Terashima K, Aqil M, Niwa M. A novel biflavonoid from the roots of *Garcinia Kola. Heterocytes* 1995; 41: 2245–50.

13. Ebana RU, Madunagu BE, Ekpe ED, Otung IN. Microbiological exploitation of cardiac glycosides and alkaloids from *Garcinia kola, Borrereria ocymoides, kola nitida* and citrus *auratifolia. J Appl Bacteroid* 1991; 71: 398–401.

14. Okunji CO, Iwu MM. Molluscidal activity of *Garcinia kola* biflavonones. *Fitoterap* 1991; 67: 74–6.

15. Hussain RA, Owegby AG, Parimoo P, Waterman PA. Kalanone, a novel polyisoprenylated benzophenone with antimicrobial properties from the fruit of *Garcinia kola. Planta Medica* 1982; 44: 78–81.

16. Bertram GK. Drugs used in asthma In: *Basic and clinical pharmacology.* 9th edition. McGraw-Hill companies. 2004. 319–33.

17. Bousquet J, Jeffery P, Busse WW, et al. Asthma: from bronchoconstriction to airway inflammation and remodeling. *Am J Respir Care Med* 2000; 161: 1720–45.

18. Nzegbule E, Mbakwe R. Effect of pre-sowing and incubation treatment on germination of *Garcinia Kola Heckel* seed. *Fruita* 2001; 56: 437–42.

19. Adesanya QA, Oluyemi KA, Ofusori DA, et al. Micromorphometric and stereological effects of ethanolic extracts of *Garcinia cambogia* seeds on the testes and epididymis of adult Wistar rats. *Int J Altern Med.* 2007; 5.

20. Manimi H, Kinoshita M, Fukuyama Y, et al. Antioxidant xanthones from *Garcinia subelliptica. Phytochem* 1994; 41: 533–629.

21. Chairungsrilerd N, Takeuchi K, Ohizumi Y, et al. Mangostanol, a prenyl xanthone from *Garcinia mangostana. Phytochem* 1996; 43: 1099–1102.

22. Irvine FR. *Woody plants of Ghana, with Special Reference to their Uses.* Oxford University Press, London. 1961; 9: 20–695.

23. Dalziel JM. *The Useful Plants of West Tropical Africa.* Crown Agents for the colonies, London. 1937.

24. Iwu MM. Food for medicine (Ed.) M. Iwu. In: *Dietary Plants and Masticatories as Sources of Biologically Active Substances.* University of Ife, Nigeria. Ife Press. 1989. 303–10.

25. Adesina SK, Gbile ZO, Odukoya OA. *Survey of indigenous plants of West Africa with special emphasis on medicinal plants and issues associated with management.* The United Nations Programme on Natural Resources in Africa; 2nd edition, 1995. 84–5.

26. Ayensu ES. *Medicinal Plants of West Africa,* Reference Publ. Inc; Algonac, Michigan. 1978. 162.

27. Ajebesone PE, Aina JO. Potential African substances for hops in tropical beer brewing. *J Food Technol Afr* 2004; 9: 13–6.

28. Akpantah AO, Oremosu AA, Noronha CC, et al. Effects of *Garcinia Kola* seed extract on ovulation, oestrous cycle and foetal development in cyclic female Sprague-Dawley rats. *Nig J Physiol Sci* 2005; 20: 58–62.

29. Braide V, Agabe CA, Essien GE, Udoh FV. Effect of *Garcinia kola* seed Alkaloid extracts on levels of Gonadal hormone and pituitary gonadotrophins in rat serum. *Nig J Physiol Sci* 2003; 18: 59–64.

30. David AO, Abiodun OA, Adebimpe EA, et al. Microanatomical effect of ethanolic extract of *Garcinia kola* on the lung of Swiss Albino mice. *Int J Pulm Med* 2008; 10(1).

31. Braide VB. Antispasmodic extracts from seeds of *Garcinia kola. Fitoterapia* 1989; ix: 123.

32. Osisiogu IUW. A preliminary thin layer chromatographic study of the seed extracts of *Garcinia kola. Current Science* 1964; 33: 552–60.

33. Orie NN, Ekon EU. The bronchodilator effects of *Garcinia kola. East Afr Med J* 1993; 70: 143–5.

34. Ebomoyi MI, Iyawe VI. Effects of *Garcinia Conrauana* ingestion on airway resistance in a population of healthy adult Nigerians. *J Med Biomed Res* 2003; 2: 22–7.

35. Lilly CM. Diversity of asthma: evolving concepts of pathophysiology and lessons from genetics. *J Allergy Clin Immunol* 2005; 115: s526–31.

36. Martinez FD. Genes, environments, development and asthma: A reappraisal. *Eur Resp J* 2007; 29: 179–84.

37. Gold DR, Wright R. Population disparities in asthma. *Annu Rev Publ Health* 2005; 26: 89–113.

38. Thavagnanam S, Fleming J, Bromley A, et al. A meta-analysis of the association between Caesarean section and childhood asthma. *Clin Exper Allergy* 2007; 38: 629–33.

39. Marra F, Lynd L, Coombes M. Does antibiotic exposure during infancy lead to development of asthma? A systematic review and meta-analysis. *Chest* 2006; 129: 610–8.

40. Ober, C Hoffjan S. Asthma genetics: the long and winding road to gene discovery. *Genes Immun* 2006; 7: 95–100.

41. Cohn L, Elias JA Chupp GL. Asthma: mechanisms of disease persistence and progression. *Annu Rev Immunol* 2004; 22: 789–815.

42. Homer RJ, Elias JA. Airway remodeling in asthma: therapeutic implications of mechanisms. *Physiol* 2005; 20: 28–35.

43. Alakija W, Iyawe VI, Jarikre LN, Chiwuzie JC. Ventilatory functions of workers at Okpella cement factory. *W Afr J Med* 1990; 9: 187–92.

44. Busse W, Banks-Schlegel S, Noel P, et al. Future research directions in asthma: an NHLBI Working Group report. *Am J Respir Crit Care Med* 2004; 170: 683–90.

45. Chakir J, Shannon J, Molet S, et al. Airway remodeling associated mediators in moderate to severe asthma: effects of steroids on TGF-BETA, IL-11, IL-17 and type I and type III collagen expression. *J Allergy Clin Immunol* 2003; 111: 1293–8.

46. Hoshino M, Nakamura Y, Sim J. Expression of growth factors and remodeling of the airway wall in bronchial asthma. *Thorax* 1998; 53: 21–7.

47. Iyawe VI, Ebomoyi MI. Current developments in the physiology and management of asthma. *Nig J Physiol Sci* 2005; 20: 19–29.

48. Miller AL. The etiologies, pathophysiology, and alternative/ complementary treatment of asthma. *Altern Med Rev* 2001; 6: 20–47.

49. Dorsch W, Wagner H. New antiasthmatic drugs from traditional medicine. *Int Arch Allergy Appl Immunol* 1991; 94: 262–5.

50. Okwu DE. Phytochemicals and vitamin content of indigenous spices of South Eastern Nigeria. *J Sustain Agric Environ* 2004; 6: 30–4.

51. Hodek P, Trefil P, Stiborova A. Flavonoids – potent and versatile biologically active compounds interacting with cytochrome P450. *Chemico-biologic Inter* 2002; 139: 1–21.

52. Ferguson LR. Role of plant polyphenols in genomic stability. *Mutat. Res* 2001; 475: 9–111.

53. Farquar JN. Plant steroids, their biological effects in humans, handbook of lipids. In: *Human Nutrition.* Boca Raton: CRC Press, 1996: 101–5.

54. Middleton E, Drzewieki G. Flavonoid inhibition of human basophil histamine release stimulated by various agents. *Biochem Pharmacol* 1984; 33: 3333–8.

55. Middleton E, Drzewieki G. Effects of flavonoids and transitional metal cations on antigen-induced histamine release from human basophils. *Biochem Pharmacol* 1982; 31: 1449–53.

56. Middleton E, Drzewieki G. Naturally occuring flavanoids and human basophil histamine release. *Int Arch Allergy Appl Immunol* 1985; 77: 155–7.

57. Simoes CM. Pharmacological investigations on Achyrocline satureioides. *J Ethnopharmacol* 1988; 22: 281–93.

58. Dahren SE, Bjork J, Hedqvist P. Leukotriens are potent constrictors of human bronchi. *Nature* 1980; 288: 484–6.

59. Hedqvist P, Dahren SE, Gustafsson L, et al. Biological profile of leukotrienes C4 and D4. *Acta Physiol Scand* 1980; 110: 331–3.

60. Pichurko BM, Ingram RH Jr., Sperting RI, et al. Localization of the site the bronchoconstrictor effects of leukotriene C4 compared with that of histamine in asthmatic subjects. *Am Rev Respir Dis* 1989; 140: 334–9.

61. Duke J. *Handbook of Biological Active Phytochemicals and their Activities.* Boca Raton: CRC Press, 1992: 99–131.